{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T22:28:26Z","timestamp":1772058506026,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2008,4,14]],"date-time":"2008-04-14T00:00:00Z","timestamp":1208131200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Radiol med"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1007\/s11547-008-0263-8","type":"journal-article","created":{"date-parts":[[2008,4,14]],"date-time":"2008-04-14T11:55:14Z","timestamp":1208174114000},"page":"895-904","source":"Crossref","is-referenced-by-count":131,"title":["Role of whole-body 18F-choline PET\/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer","Ruolo dell\u2019esame PET\/TC con 18F-colina nell\u2019identificazione di malattia in pazienti sottoposti a trattamento radicale per neoplasia prostatica, con attuale recidiva biochimica"],"prefix":"10.1007","volume":"113","author":[{"given":"E.","family":"Pelosi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Arena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Skanjeti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Pirro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Douroukas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pupi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,4,14]]},"reference":[{"issue":"1","key":"263_CR1","doi-asserted-by":"crossref","first-page":"i34","DOI":"10.1093\/annonc\/mdi032","volume":"16","author":"ESMO","year":"2005","unstructured":"ESMO (2005) Minimum clinical recommendations for diagnosis, treatment and follow-up of prostate cancer. Ann Oncol 16(Suppl 1):i34\u2013i36","journal-title":"Ann Oncol"},{"key":"263_CR2","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1158\/1078-0432.CCR-05-0249","volume":"11","author":"H. Schoder","year":"2005","unstructured":"Schoder H, Herrmann K, Gonen M et al (2005) 2-[18F]fluoro-2-deoxiglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res 11:4761\u20134769","journal-title":"Clin Cancer Res"},{"key":"263_CR3","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1200\/JCO.2004.04.579","volume":"22","author":"D. Loblaw","year":"2004","unstructured":"Loblaw D, Mendelson DS, Talcott JA et al (2004) American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 22:2927\u20132941","journal-title":"J Clin Oncol"},{"key":"263_CR4","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/0090-4295(94)90180-5","volume":"43","author":"A.W. Partin","year":"1994","unstructured":"Partin AW, Pearson JD, Landis PK et al (1994) Evaluation of serum prostate specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 43:649\u2013659","journal-title":"Urology"},{"issue":"5","key":"263_CR5","first-page":"1S","volume":"42","author":"S.S. Gambhir","year":"2001","unstructured":"Gambhir SS, Czernin J, Schwimmer J et al (2001) A tabulated summary of the FDG PET literature. J Nuc Med 42(5 Suppl):1S\u201393S","journal-title":"J Nuc Med"},{"key":"263_CR6","first-page":"1805","volume":"42","author":"T.R. DeGrado","year":"2001","unstructured":"DeGrado TR, Baldwin SW, Wang S et al (2001) Synthesis and evaluation of 18F-labeled choline analogs as oncologic PET tracers. J Nucl Med 42:1805\u20131814","journal-title":"J Nucl Med"},{"key":"263_CR7","first-page":"187","volume":"43","author":"T. Hara","year":"2002","unstructured":"Hara T, Kosaka N, Kishi H (2002) Development of 18F-Fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J Nucl Med 43:187\u2013199","journal-title":"J Nucl Med"},{"key":"263_CR8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.semnuclmed.2005.09.001","volume":"36","author":"S. Jana","year":"2006","unstructured":"Jana S, Blaufox MD (2006) Nuclear medicine studies of the prostate, testes, and bladder. Semin Nucl Med 36:51\u201372","journal-title":"Semin Nucl Med"},{"key":"263_CR9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1053\/j.semnuclmed.2005.09.002","volume":"36","author":"W. Langsteger","year":"2006","unstructured":"Langsteger W, Heinisch M, Fogelman I (2006) The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18Fcholine, and 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med 36:73\u201392","journal-title":"Semin Nucl Med"},{"key":"263_CR10","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1148\/radiol.2352040494","volume":"235","author":"D.T. Schmidt","year":"2005","unstructured":"Schmidt DT, John H, Zweifel R et al (2005) Fluorocholine PET\/CT in patients with prostate cancer: initial experience. Radiology 235:623\u2013628","journal-title":"Radiology"},{"key":"263_CR11","first-page":"262","volume":"47","author":"S.A. Kwee","year":"2006","unstructured":"Kwee SA, Wei H, Sesterhenn I et al (2006) Localization of primary prostate cancer with Dual-Phase 18FFluorocholine PET. J Nucl Med 47:262\u2013269","journal-title":"J Nucl Med"},{"key":"263_CR12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11307-005-0023-2","volume":"8","author":"M. Heinisch","year":"2006","unstructured":"Heinisch M, Dirisamer A, Loidl W et al (2006) Positron emission tomography\/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA<5 ng\/ml? Mol Imaging Biol 8:43\u201348","journal-title":"Mol Imaging Biol"},{"key":"263_CR13","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s00259-006-0150-2","volume":"33","author":"M. Cimitan","year":"2006","unstructured":"Cimitan M, Bortolus R, Morassut S et al (2006) [(18)F]fluorocholine PET\/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 33:1387\u20131398","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"263_CR14","first-page":"3599","volume":"61","author":"E. Ackerstaff","year":"2001","unstructured":"Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM (2001) Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res 61:3599\u20133603","journal-title":"Cancer Res"},{"key":"263_CR15","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1148\/radiol.2312030011","volume":"231","author":"T. Sella","year":"2004","unstructured":"Sella T, Schwartz LH, Swindle PW et al (2004) Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 231:379\u2013385","journal-title":"Radiology"},{"key":"263_CR16","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1148\/radiol.2362040739","volume":"236","author":"D. Pucar","year":"2005","unstructured":"Pucar D, Shukla-Dave A, Hricak H et al (2005) Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy \u2014 initial experience. Radiology 236:545\u2013553","journal-title":"Radiology"},{"key":"263_CR17","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0022-5347(05)67370-3","volume":"164","author":"A.E. Wefer","year":"2000","unstructured":"Wefer AE, Hricak H, Vigneron DB et al (2000) Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 164:400\u2013404","journal-title":"J Urol"},{"key":"263_CR18","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1148\/radiol.2332032086","volume":"233","author":"F.V. Coakley","year":"2004","unstructured":"Coakley FV, The HS, Qayyum A et al (2004) Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology 233:441\u2013448","journal-title":"Radiology"},{"key":"263_CR19","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1053\/j.semnuclmed.2004.06.004","volume":"34","author":"H. Schoder","year":"2004","unstructured":"Schoder H, Larson SM (2004) Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 34:274\u2013292","journal-title":"Semin Nucl Med"},{"key":"263_CR20","first-page":"1485","volume":"10","author":"H. Jadvar","year":"2003","unstructured":"Jadvar H, Pinski JK, Conti PS (2003) FDG-PET in suspected recurrent and metastatic prostate cancer. Oncol Rep 10:1485\u20131488","journal-title":"Oncol Rep"},{"key":"263_CR21","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00259-006-0163-x","volume":"34","author":"S. Albrecht","year":"2007","unstructured":"Albrecht S, Buchegger F, Soloviev D et al (2007) (11)C-acetate PET in the early evaluation of prostate cancer recurrence. Eur J Nucl Med Mol Imaging 34:185\u2013196","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"263_CR22","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00259-006-0281-5","volume":"34","author":"M.J. Morris","year":"2007","unstructured":"Morris MJ, Scher HI (2007) (11)Cacetate PET imaging in prostate cancer. Eur J Nucl Med Mol Imaging 34:181\u2013184","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"263_CR23","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.urology.2005.11.044","volume":"67","author":"G. Sandblom","year":"2006","unstructured":"Sandblom G, Sorensen J, Lundin N et al (2006) Positron emission tomography with C11-Acetate for tumour detection and localization in patients with prostate-specific-antigen relapse after radical prostatectomy. Urology 67:996\u20131000","journal-title":"Urology"},{"key":"263_CR24","first-page":"990","volume":"39","author":"T. Hara","year":"1998","unstructured":"Hara T, Kosaka N, Kishi H (1998) PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 39:990\u2013995","journal-title":"J Nucl Med"},{"key":"263_CR25","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1097\/01.ju.0000056901.95996.43","volume":"169","author":"M. Picchio","year":"2003","unstructured":"Picchio M, Messa C, Landoni C et al (2003) Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]Fluorodeoxyglucose-positron emission tomography. J Urol 169:1337\u20131340","journal-title":"J Urol"},{"key":"263_CR26","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0302-2838(03)00207-0","volume":"44","author":"I. Jong De","year":"2003","unstructured":"De Jong I, Pruim J, Elsinga PH et al (2003) 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 44:32\u201338","journal-title":"Eur Urol"},{"key":"263_CR27","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000083551","volume":"74","author":"S. Yoshida","year":"2005","unstructured":"Yoshida S, Nakagomi K, Goto S et al (2005) 11C-choline positron emission tomography in prostate cancer: primary staging and recurrent site staging. Urol Int 74:214\u2013220","journal-title":"Urol Int"},{"key":"263_CR28","first-page":"331","volume":"44","author":"I. Jong de","year":"2003","unstructured":"de Jong I, Pruim J, Elsinga PH et al (2003) Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 44:331\u2013335","journal-title":"J Nucl Med"},{"key":"263_CR29","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s00259-004-1755-y","volume":"32","author":"T. Yamaguchi","year":"2005","unstructured":"Yamaguchi T, Lee J, Uemura H et al (2005) Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Med Mol Imaging 32:742\u2013748","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["La radiologia medica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-008-0263-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11547-008-0263-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-008-0263-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T12:21:50Z","timestamp":1559391710000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11547-008-0263-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,14]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["263"],"URL":"https:\/\/doi.org\/10.1007\/s11547-008-0263-8","relation":{},"ISSN":["0033-8362","1826-6983"],"issn-type":[{"value":"0033-8362","type":"print"},{"value":"1826-6983","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,14]]}}}